3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Neoplasm Metastasis
3
Stomatitis
2
Stomach Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Lipoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intracranial Hemorrhages
1
Interventions
Azacitidine
142
Cytarabine
109
venetoclax
94
fludarabine
35
Daunorubicin
34
Decitabine
32
Idarubicin
26
gilteritinib
24
Cyclophosphamide
21
quizartinib
15
midostaurin
15
Mitoxantrone
14
Etoposide
14
Granulocyte Colony-Stimulating Factor
12
Gemtuzumab
11
CPX-351
11
decitabine and cedazuridine drug combination
10
Drug Therapy
10
cc-486
9
Filgrastim
9
Clofarabine
9
ivosidenib
8
Injections
8
Dexamethasone
8
pevonedistat
7
fludarabine phosphate
7
AP 1903 reagent
7
posaconazole
6
magrolimab
6
glasdegib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Myeloid, Acute
×
Saline Solution
×
Clear all
NCT04571645
2024-04-15
AML
Jazz Pharmaceuticals
Phase 3
Terminated
9 enrolled
9 charts
NCT01687387
2019-02-08
EFFIKIR
Innate Pharma
Phase 2
Completed
152 enrolled
9 charts